← Back to feed

Genedrive

GDR · AIM · Health Care · mcap £18m today

All announcements

All RNS · 60 Key events · 41

10 Sep 26

Welsh hospitals extend routine MT-RNR1 testing

Welsh hospitals extend routine clinical service of genedrive's MT-RNR1 test
RNS 9764379 ↗
03 Sep 26

ShareSoc Investor Presentation Reminder

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, is conducting a ShareSoc webinar at 11:00am (BST) today.
RNS 9752918 ↗
01 Sep 26

Director/PDMR Shareholding Director buys

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company announces that on 28 August 2026, Dr Gino Miele, Chief Executive Officer, acquired 700,000 Ordinary Shares in the Company at a price of 1.38p per share and Russ Shaw, Chief...
RNS 9747220 ↗
21 Aug 26

Board Appointments

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, today announces that Mr Mark Winkler and Mr Mike Fairbourn have agreed to join the Board as independent Non-Executive Directors with effect from 1 September 2026.
RNS 9733060 ↗
13 Aug 26

ShareSoc Investor Presentation

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, is pleased to announce that it will be presenting a live ShareSoc webinar on Thursday 3 September 2026 at 11:00am (BST).
RNS 9719092 ↗
11 Aug 26

Completion of PALOH-UK Patient Recruitment

Completion of PALOH-UK Patient Recruitment for Genedrive® MT-RNR1 ID Kit
RNS 9714394 ↗
04 Aug 26

MT-RNR1 test implemented in the Netherlands

Genedrive® MT-RNR1 ID Kit implemented at Erasmus MC University Medical Center in the Netherlands
RNS 9702462 ↗
03 Aug 26

New UK clinical guideline for MT-RNR1 testing

New UK clinical guideline published for MT-RNR1 genotype testing
RNS 9699751 ↗
14 Jul 26

Board Appointment

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, today announces that Mr.
RNS 9666668 ↗
13 Jul 26

Trading Update

- Strong commercial progress and poised for continued growth in the next 12 months
RNS 9664190 ↗
10 Jul 26

UK Minister highlights pharmacogenetic testing

UK Health Minister highlights NIHR Manchester Biomedical Research Centre's adoption of rapid pharmacogenetic testing for antibiotic-induced hearing loss during Parliamentary Committee
RNS 9662012 ↗
01 Jul 26

Directorate Change

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, today announces that further to the Company's announcement of 26 May 2026 detailing various immediate and proposed board changes, Dr.
RNS 9645681 ↗
29 Jun 26

CYP2C19 Agreement with Thermo Fisher Scientific

CYP2C19 Product Development Collaboration agreement with Thermo Fisher Scientific Inc.
RNS 9640370 ↗
18 Jun 26

Manchester NHS Trust transitions MT-RNR1 to BAU

Manchester University NHS Foundation Trust transitions genedrive's MT-RNR1 test to Business as Usual clinical service
RNS 9624285 ↗
05 Jun 26

Receipt of R&D tax credit

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, confirms it has received an R&D tax credit refund of approximately £0.76m from HMRC in respect of the financial years ended 30 June 2024 and 30 June 2025.
RNS 9603094 ↗
01 Jun 26

Block Listing Returns
RNS 9593403 ↗
26 May 26

Directorate Change

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, today announces that Mr David Nugent has joined the Board as a Non-Executive Director with immediate effect.
RNS 9583927 ↗
06 May 26

Holding(s) in Company Holder at 25–30 %

TR-1: Standard form for notification of major holdings
RNS 9555067 ↗
05 May 26

Sussex NHS Trust transitions MT-RNR1 test to BAU

University Hospitals Sussex NHS Foundation Trust transitions genedrive's MT-RNR1 test to Business as Usual clinical service
RNS 9550716 ↗
21 Apr 26

NHS England commercial strategy for MT-RNR1

Consultation to inform NHS England commercial strategy for rapid MT-RNR1 testing
RNS 9529324 ↗
20 Apr 26

Interactive Investor Hub Updates

genedrive Updates Interactive Investor Hub to Support Shareholder Engagement
RNS 9527023 ↗
16 Apr 26

CYP2C19 kit implemented in North Bristol NHS Trust

Implementation of Genedrive® CYP2C19 ID Kit in North Bristol NHS Trust Southmead Hospital
RNS 9522671 ↗
30 Mar 26

Half-year Results

- Capitalised to expand commercial operations in the UK and internationally
RNS 9496991 ↗
12 Mar 26

Holding(s) in Company
RNS 9471487 ↗
12 Mar 26

Holding(s) in Company
RNS 9470352 ↗
11 Mar 26

Holding(s) in Company
RNS 9469877 ↗
09 Mar 26

Result of General Meeting
RNS 9465065 ↗
09 Mar 26

Result of Open Offer and Additional Subscriptions

Manchester, UK - 9 March 2026: genedrive plc (LSE: GDR), the point of care pharmacogenetic testing company, announces that that it has conditionally raised total gross proceeds of approximately £0.91 million through the Open Offer which was announced on 13...
RNS 9463535 ↗
24 Feb 26

Holding(s) in Company
RNS 9444948 ↗
24 Feb 26

Holding(s) in Company
RNS 9444758 ↗
19 Feb 26

Publication of circular, notice of GM & timetable
RNS 9437302 ↗
13 Feb 26

Completion of Placing

Manchester, UK - 13 February 2026: genedrive plc (LSE: GDR), the point of care pharmacogenetic testing company, announces the completion of the placing (the "Placing") which was announced earlier today.
RNS 9431027 ↗
13 Feb 26

Proposed Direct Subscription to raise up to £3.5m

Proposed Direct Subscription to raise up to £3.5 million, Placing to raise up to £0.5 million and an Open Offer to raise up to circa £1.5 million to support various growth initiatives (the "Fundraising")
RNS 9430830 ↗
06 Feb 26

Holding(s) in Company
RNS 9414746 ↗
03 Feb 26

Holding(s) in Company
RNS 9404982 ↗
27 Jan 26

Holding(s) in Company
RNS 9389710 ↗
19 Jan 26

Proposed equity raise of up to £6.0 million

Significant indicated support from two major shareholders for an equity raise of up to £6.0 million
RNS 9366286 ↗
31 Dec 25

Result of AGM
RNS 9327405 ↗
18 Dec 25

Scotland NHS “test of change” pilot programme

Genedrive's CYP2C19 ID kit piloted as a "test of change" in Scotland NHS Grampian and Western Isles
RNS 9305028 ↗
11 Dec 25

New interactive investor hub

genedrive plc (LSE: GDR), the point of care pharmacogenetic testing company, is pleased to announce the launch of our interactive investor hub.
RNS 9290304 ↗
09 Dec 25

Agreement of Shareholder Loan

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, is pleased to announce that further to the announcement of 19 November 2025 confirming that heads of term had been agreed for a potential shareholder loan (the "Loan") from David...
RNS 9285824 ↗
08 Dec 25

Annual Report and Accounts and date of AGM

Annual Report and Accounts and date of AGM
RNS 9283134 ↗
05 Dec 25

Final Results

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, announces its audited Final Results for the year ended 30 June 2025.
RNS 9277392 ↗
03 Dec 25

Notice of Results
RNS 9271971 ↗
01 Dec 25

Block Listing Returns
RNS 9268259 ↗
01 Dec 25

Results presented re. NHS CYP2C19 Genotype Testing

Pilot Programme Study Results underpinning NHS Implementation Guide for CYP2C19 Genotype Testing Presented at the UK Stroke Forum
RNS 9266115 ↗
27 Nov 25

NHS implementation guide published for CYP2C19

NHS implementation guide published for CYP2C19 genotype testing
RNS 9261168 ↗
26 Nov 25

Scotland national roll-out of MT-RNR1 ID Kit

Scotland national roll-out of Genedrive® MT-RNR1 ID Kit
RNS 9257295 ↗
19 Nov 25

Further re Shareholder Loan

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, is pleased to announce that further to the announcement of 31 October 2025 in relation to a potential shareholder loan (the "Loan") from David Nugent, a significant shareholder in...
RNS 9242655 ↗
04 Nov 25

MT-RNR1 ID Kit in Dublin’s Rotunda Hospital

Genedrive® MT-RNR1 ID Kit implemented at Dublin's Rotunda Hospital
RNS 9210218 ↗
31 Oct 25

Potential Shareholder Loan

genedrive plc (AIM: GDR), the point-of-care pharmacogenetic testing company, today announces an update regarding discussions with David Nugent, a 16% shareholder in the Company including via a limited company.
RNS 9205109 ↗
29 Oct 25

Holding(s) in Company
RNS 9202451 ↗
28 Oct 25

MOU with Kingdom of Saudi Arabia for MT-RNR1 ID

Memorandum of Understanding with Kingdom of Saudi Arabia Ministry of Health
RNS 9197710 ↗
24 Oct 25

Application for Listing & Total Voting Rights

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, confirms that warrants have been exercised that were issued in connection to the Equity Prepayment facility that was announced on 31 March 2023.
RNS 9193491 ↗
15 Oct 25

Result of General Meeting
RNS 9172693 ↗
10 Oct 25

Holding(s) in Company
RNS 9164037 ↗
10 Oct 25

Holding(s) in Company
RNS 9164036 ↗
10 Oct 25

Holding(s) in Company
RNS 9163353 ↗
09 Oct 25

Further re Equity Financing

genedrive plc (LSE: GDR) Further to the Company's announcement on 6 October 2025 the Company has noted extensive postings on online bulletin boards which it believes to be made by David Nugent ("the Shareholder"), a 10.1% shareholder in the Company as of 2...
RNS 9160873 ↗
06 Oct 25

Further re Equity Financing

genedrive plc (LSE: GDR), the point of care pharmacogenetic testing company today responds to comments and speculation on online bulletin boards that other financing options may have been available to the Company and/or that the Company may have been in...
RNS 9151436 ↗

Source: Investegate RNS archive. Quotes are short extracts. Not investment advice.